A Study to Evaluate Addition of Peginterferon Alfa-2a to Chronic Hepatitis B (CHB) Patients Treated With NAs
A Randomized, Open-label, Multi-center Clinical Trial to Evaluate Addition of Peginterferon Alfa-2a to CHB Patients Treated With NAs and Achieved HBV DNA<15 IU/ml、HBeAg<100 PEIU/ml、HBsAg Positive and HBsAg<1500 IU/ml.
Sponsor: Henan Provincial People's Hospital
Listed as NCT02894918, this PHASE4 trial focuses on Chronic Hepatitis B and remains ongoing. Sponsored by Henan Provincial People's Hospital, it has been updated 7 times since 2016, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.
Status Flow
Change History
7 versions recorded-
Sep 2024 — Present [monthly]
Unknown PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE4
Status: Unknown Status → Unknown
-
Jan 2021 — Jul 2024 [monthly]
Unknown Status PHASE4
-
Apr 2020 — Jan 2021 [monthly]
Unknown Status PHASE4
-
Jan 2019 — Apr 2020 [monthly]
Unknown Status PHASE4
Status: Active Not Recruiting → Unknown Status
▶ Show 2 earlier versions
-
Jun 2018 — Jan 2019 [monthly]
Active Not Recruiting PHASE4
-
Jan 2017 — Jun 2018 [monthly]
Active Not Recruiting PHASE4
First recorded
Sep 2016
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Henan Provincial People's Hospital
For direct contact, visit the study record on ClinicalTrials.gov .